mk-0616
Small moleculeexperimental
Clinical trial activity
30 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
22
Phase 2
7
Phase 3
7
Phase 4
0
Earliest trial started Nov 16, 2021 (NCT05070390)
Timeline
Indications
Studied for
- Arteriosclerosis · Phase 3
- Healthy Volunteers · Phase 1
- Hepatic Insufficiency · Phase 1
- Homozygous Familial Hypercholesterolemia · Phase 2/Phase 3
- Hypercholesterolemia · Phase 3
- Hyperlipidemias · Phase 3
- Hyperlipoproteinemia Type II · Phase 3
- Kidney Diseases · Phase 1
- Kidney Failure, Chronic · Phase 1
- Liver Diseases · Phase 1
Mechanism of action
- Subtilisin/kexin type 9ANTAGONIST
PCSK9 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
COc1ccc(C[C@@H]2NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H]3[C@@H]4CCN3C(=O)[C@@H]3Cc5cn(c6ccc(F)cc56)CCCCCCN(Cc5ccc(cc5)CCNC(=O)[C@]5(C)CCCN5C2=O)C(=O)CCC(=O)N[C@@H](C)C(=O)N[C@H](CNC(=O)CCCCC[N+](C)(C)C)C(=O)N[C@@H](Cc2cccc(c2)CNC(=O)CO4)C(=O)N3)cc1.[Cl-]- Mol. weight
- 1586.32 g/mol
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL6068773 ↗
- ChEMBLCHEMBL6068420 ↗
- ChEMBLCHEMBL6067978 ↗
- ChEMBLCHEMBL5314738 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07300280 | Phase 1 | Dec 29, 2025 | Merck |
| NCT07216482 | Phase 3 | Nov 11, 2025 | Merck |
| NCT07058077 | Phase 2/Phase 3 (Phase 3) | Aug 21, 2025 | Merck |
| NCT07044479 | Phase 1 | Jul 3, 2025 | Merck |
| NCT06880874 | Phase 1 | Apr 2, 2025 | Merck |
| NCT06818968 | Phase 1 | Feb 27, 2025 | Merck |
| NCT06719544 | Phase 1 | Jan 2, 2025 | Merck |
| NCT06643377 | Phase 1 | Nov 13, 2024 | Merck |
| NCT06609512 | Phase 1 | Oct 21, 2024 | Merck |
| NCT06597760 | Phase 1 | Oct 7, 2024 | Celerion, Merck |
| NCT06575959 | Phase 1 | Sep 20, 2024 | Merck |
| NCT06492291 | Phase 3 | Aug 5, 2024 | Merck |
| NCT06625814 | Phase 1 | Jul 8, 2024 | Celerion, Merck |
| NCT06450366 | Phase 3 | Jul 8, 2024 | Merck |
| NCT06772792 | Phase 1 | Apr 23, 2024 | Merck |
| NCT06772779 | Phase 1 | Apr 1, 2024 | Merck |
| NCT06691906 | Phase 1 | Mar 18, 2024 | Merck |
| NCT06699329 | Phase 1 | Jan 22, 2024 | Merck |
| NCT06699355 | Phase 1 | Nov 8, 2023 | Merck |
| NCT06658652 | Phase 1 | Oct 24, 2023 | Merck |
Showing 20 of 30 trials
Page 1 / 2